WO1997017085A3 - A method for inhibiting attachment of h. influenzae to human cells using phosphorylated recombinant human beta-casein - Google Patents

A method for inhibiting attachment of h. influenzae to human cells using phosphorylated recombinant human beta-casein Download PDF

Info

Publication number
WO1997017085A3
WO1997017085A3 PCT/US1996/017860 US9617860W WO9717085A3 WO 1997017085 A3 WO1997017085 A3 WO 1997017085A3 US 9617860 W US9617860 W US 9617860W WO 9717085 A3 WO9717085 A3 WO 9717085A3
Authority
WO
WIPO (PCT)
Prior art keywords
casein
recombinant human
phosphorylated recombinant
influenzae
cells
Prior art date
Application number
PCT/US1996/017860
Other languages
French (fr)
Other versions
WO1997017085A9 (en
WO1997017085A2 (en
Inventor
Pradip Mukerji
Jennifer M Thurmond
Lennart Hansson
Jeffrey H Baxter
Robert G Hards
Amanda Eun-Yeong Leonard
Steven N Anderson
Linda A Harvey
Original Assignee
Abbott Lab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Abbott Lab filed Critical Abbott Lab
Priority to NZ322369A priority Critical patent/NZ322369A/en
Priority to CA002234664A priority patent/CA2234664A1/en
Priority to JP9518321A priority patent/JP2000500141A/en
Priority to EP96938817A priority patent/EP0862450A2/en
Priority to AU76104/96A priority patent/AU7610496A/en
Publication of WO1997017085A2 publication Critical patent/WO1997017085A2/en
Publication of WO1997017085A9 publication Critical patent/WO1997017085A9/en
Publication of WO1997017085A3 publication Critical patent/WO1997017085A3/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4732—Casein
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/17—Amino acids, peptides or proteins
    • A23L33/19—Dairy proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/16—Otologicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Oncology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Communicable Diseases (AREA)
  • Polymers & Plastics (AREA)
  • Biochemistry (AREA)
  • Nutrition Science (AREA)
  • Mycology (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Food Science & Technology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicinal Preparation (AREA)
  • Dairy Products (AREA)

Abstract

A method is provided for inhibiting the attachment of H. influenzae to human cells, such as pharyngeal cells, by contacting the bacilli with phosphorylated recombinant human β-casein that have at least 3 phosphate groups. A product containing phosphorylated recombinant human β-casein may be a liquid enteral nutritional product such as infant formula. The enteral nutritional product may be used for the prevention and treatment of otitis media in infants. The phosphorylated recombinant human β-casein may also be administered as a throat spray or used in nose drops or a spray.
PCT/US1996/017860 1995-11-06 1996-11-06 A method for inhibiting attachment of h. influenzae to human cells using phosphorylated recombinant human beta-casein WO1997017085A2 (en)

Priority Applications (5)

Application Number Priority Date Filing Date Title
NZ322369A NZ322369A (en) 1995-11-06 1996-11-06 Use of phosphorylated BETA H.influenzae
CA002234664A CA2234664A1 (en) 1995-11-06 1996-11-06 A method for inhibiting attachment of h. influenzae to human cells using phosphorylated recombinant human beta-casein
JP9518321A JP2000500141A (en) 1995-11-06 1996-11-06 Method for inhibiting adhesion of Haemophilus influenzae to human cells using phosphorylated recombinant human beta-casein
EP96938817A EP0862450A2 (en) 1995-11-06 1996-11-06 A method for inhibiting attachment of h. influenzae to human cells using phosphorylated recombinant human beta-casein
AU76104/96A AU7610496A (en) 1995-11-06 1996-11-06 A method for inhibiting attachment of h. influenzae to human cells using phosphorylated recombinant human beta-casein

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US55252995A 1995-11-06 1995-11-06
US08/552,529 1995-11-06

Publications (3)

Publication Number Publication Date
WO1997017085A2 WO1997017085A2 (en) 1997-05-15
WO1997017085A9 WO1997017085A9 (en) 1997-06-26
WO1997017085A3 true WO1997017085A3 (en) 1997-08-07

Family

ID=24205731

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US1996/017860 WO1997017085A2 (en) 1995-11-06 1996-11-06 A method for inhibiting attachment of h. influenzae to human cells using phosphorylated recombinant human beta-casein

Country Status (6)

Country Link
EP (1) EP0862450A2 (en)
JP (1) JP2000500141A (en)
AU (1) AU7610496A (en)
MX (1) MX9803565A (en)
NZ (1) NZ322369A (en)
WO (1) WO1997017085A2 (en)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5942254A (en) * 1995-02-27 1999-08-24 Abbott Laboratories Phosphorylated recombinant human β-casein expressed in a bacterial system
ATE246934T1 (en) * 1995-11-06 2003-08-15 Abbott Lab PHOSPHORYLATED RECOMBINANT HUMAN BETA CASEIN FOR INHIBITING THE ADDHESION OF H. INFLUENZAE TO HUMAN CELLS
KR101188292B1 (en) 2002-11-27 2012-10-09 디엠아이 바이오사이언시스, 인크 Treatment of diseases and conditions mediated by increased phosphorylation
US7332179B2 (en) 2003-12-12 2008-02-19 Kimberly-Clark Worldwide, Inc. Tissue products comprising a cleansing composition
US7642395B2 (en) 2004-12-28 2010-01-05 Kimberly-Clark Worldwide, Inc. Composition and wipe for reducing viscosity of viscoelastic bodily fluids

Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1991006308A1 (en) * 1989-10-30 1991-05-16 Bengt Andersson A casein fraction for therapeutic, profylactic and/or diagnostic use in infections of the respiratory tract
WO1991008675A1 (en) * 1989-12-20 1991-06-27 Slattery Charles W Human infant formulas containing recombinant human alpha-lactalbumin and beta-casein
WO1993004171A1 (en) * 1991-08-19 1993-03-04 Symbicom Aktiebolag Human beta-casein, process for producing it and use thereof
WO1994006306A1 (en) * 1992-09-22 1994-03-31 New Zealand Dairy Board A process for producing beta-casein enriched products
WO1995032727A1 (en) * 1994-05-26 1995-12-07 Abbott Laboratories Inhibition of infection of mammalian cells by respiratory syncytial virus
WO1995032728A1 (en) * 1994-05-26 1995-12-07 Abbott Laboratories Inhibition of attachment of h. influenzae to human cells
WO1996027018A1 (en) * 1995-02-27 1996-09-06 Abbott Laboratories A plasmid for expressing modified recombinant proteins in a bacterial system

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5807702A (en) * 1995-02-27 1998-09-15 Abbott Laboratories Method for expressing phosphorylated recombinant human β-casein in a bacterial system
ATE246934T1 (en) * 1995-11-06 2003-08-15 Abbott Lab PHOSPHORYLATED RECOMBINANT HUMAN BETA CASEIN FOR INHIBITING THE ADDHESION OF H. INFLUENZAE TO HUMAN CELLS

Patent Citations (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1991006308A1 (en) * 1989-10-30 1991-05-16 Bengt Andersson A casein fraction for therapeutic, profylactic and/or diagnostic use in infections of the respiratory tract
WO1991008675A1 (en) * 1989-12-20 1991-06-27 Slattery Charles W Human infant formulas containing recombinant human alpha-lactalbumin and beta-casein
WO1993004171A1 (en) * 1991-08-19 1993-03-04 Symbicom Aktiebolag Human beta-casein, process for producing it and use thereof
WO1993004172A2 (en) * 1991-08-19 1993-03-04 Symbicom Aktiebolag Gene encoding a human beta-casein process for obtaining the protein and use thereof in an infant formula
WO1994006306A1 (en) * 1992-09-22 1994-03-31 New Zealand Dairy Board A process for producing beta-casein enriched products
WO1995032727A1 (en) * 1994-05-26 1995-12-07 Abbott Laboratories Inhibition of infection of mammalian cells by respiratory syncytial virus
WO1995032728A1 (en) * 1994-05-26 1995-12-07 Abbott Laboratories Inhibition of attachment of h. influenzae to human cells
WO1996027018A1 (en) * 1995-02-27 1996-09-06 Abbott Laboratories A plasmid for expressing modified recombinant proteins in a bacterial system

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
C.SVANBORG ET AL.: "ANTI-ADHESIVE MOLECULES IN HUMAN MILK", ADV.EXP.MED.BIOL., vol. 310, 1991, pages 167 - 171, XP000674221 *
G.ANIANSSON ET AL.: "Anti-adhesive activity of human casein against Streptococcus pneumoniae and Haemophilus influenzae", MICROB.PATHOG., vol. 8, no. 5, May 1990 (1990-05-01), pages 315 - 323, XP000674222 *

Also Published As

Publication number Publication date
JP2000500141A (en) 2000-01-11
MX9803565A (en) 1998-09-30
AU7610496A (en) 1997-05-29
EP0862450A2 (en) 1998-09-09
NZ322369A (en) 1999-11-29
WO1997017085A2 (en) 1997-05-15

Similar Documents

Publication Publication Date Title
EP0486425A3 (en) High acid system nutritional formulations
CA2143420A1 (en) Medical Foods for the Nutritional Support of Infant/Toddler Metabolic Diseases
AU4180593A (en) The use of complement inhibitors for the preparation of a pharmaceutical for the prophylaxis and therapy of inflammatory intestinal and skin disorders as well as purpura
AU5160993A (en) Bifidobacterium growth promoter
EP1013284A3 (en) Purified forms of dnase
DE69331296D1 (en) Low caloric enteral formula for reducing diarrhea in tube-fed patients
EP0189160A3 (en) High fat, low carbohydrate enteral nutritional formula
AU7912194A (en) Method for treatment for pulmonary disease
ATE145554T1 (en) USE OF LIPIDS CONTAINING SHORT CHAIN FATTY ACIDS TO MAINTAIN THE INTEGRITY AND FUNCTION OF THE GASTROINTESTINAL CHANNEL
WO1997017085A3 (en) A method for inhibiting attachment of h. influenzae to human cells using phosphorylated recombinant human beta-casein
Larson et al. Frequency of eating as a factor in experimental dental caries
JPS57206608A (en) Production of gamma-globulin for intravenous injection
WO1997026320A3 (en) Product for inhibition of attachment of h. influenzae to human cells
GB8402573D0 (en) Oral formulation
GB8916734D0 (en) Pharmaceutical and dietary uses of fatty acids
HUT49284A (en) Process for production of medical compositions applicable "in loco" against androgene hairlessness
GR3031086T3 (en) Enantiomerically-enhanced nutritional energy substrates
Harris et al. Sodium preference in food and previous dietary experience in 6-month-old infants.
FR2618305B1 (en) NUTRITIONAL MIXTURE FOR THE ELDERLY
HU9201412D0 (en) Process for the enzymatic hydrolysis of carbonic acid derivatives
MX9605829A (en) Inhibition of attachment of h. influenzae to human cells.
Shaw The role of sugar in the aetiology of dental caries: 6. Evidence from experimental animal research
GB2182558A (en) Oral fructo-oligosaccharide pharmaceutical compositions
Utian Non-hormonal medication
NZ329311A (en) use of beta-casein to inhibit infection in mammalian cells by respiratory syncytial virus

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AU CA JP MX NZ

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): AT BE CH DE DK ES FI FR GB GR IE IT LU MC NL PT SE

COP Corrected version of pamphlet

Free format text: PAGES 1-32,DESCRIPTION,REPLACED BY NEW PAGES 1-35;PAGES 33-35,CLAIMS,REPLACED BY NEW PAGES 36-39;PAGES 1/11-11/11,DRAWINGS,REPLACED BY NEW PAGES BEARING THE SAME NUMBER;DUE TO LATE TRANSMITTAL BY THE RECEIVING OFFICE

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
121 Ep: the epo has been informed by wipo that ep was designated in this application
WWE Wipo information: entry into national phase

Ref document number: 322369

Country of ref document: NZ

ENP Entry into the national phase

Ref document number: 1997 518321

Country of ref document: JP

Kind code of ref document: A

Ref document number: 2234664

Country of ref document: CA

Kind code of ref document: A

Ref document number: 2234664

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: PA/a/1998/003565

Country of ref document: MX

Ref document number: 1996938817

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 1996938817

Country of ref document: EP

WWW Wipo information: withdrawn in national office

Ref document number: 1996938817

Country of ref document: EP